Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma

Inclusion Criteria: * Signed consent form. * Male or non-pregnant, non-lactating female, ≥ 18 years. * Must have a previously untreated, histologically confirmed nBCC on head, neck, trunk or arms. * nBCC must not be larger than 20 mm in diameter and must be less than 5 mm in depth. * Willing and able to participate in the trial as an outpatient and comply with all trial requirements. Exclusion Criteria: * nBCC located close to or at mouth or eyes. * Patients who have had an organ transplant. * Known autoimmune disorder (especially psoriasis), impaired immune system (e.g. HIV), known thyroid abnormalities, known depression. * An open wound or an infection in treatment area. * Dermatological disease or condition (e.g. rosacea, atopic dermatitis, eczema) in the treatment or surrounding area that might impair trial assessments. * Evidence of an active infection or systemic cancer. * Flu or flu-like symptoms (including general indisposition, fever, nausea, muscle pain, chills) within a week before start of the trial. * Known allergy or hypersensitivity to any of the trial gel ingredients. * Evidence of unstable or uncontrolled clinically significant medical conditions as determined by the investigator (e.g., renal or hepatic disease). * Current alcohol abuse or chemical dependency as assessed by the investigator. * Patient who is detained or committed to an institution by a law court or by legal authorities. * Participation in another clinical trial within one month before star…